Reuters logo
5 个月内
BRIEF-Fibrogen wins China clearance to conduct key study testing roxadustat
2017年3月31日 / 下午1点34分 / 5 个月内

BRIEF-Fibrogen wins China clearance to conduct key study testing roxadustat

1 分钟阅读

March 31 (Reuters) - Fibrogen Inc

* Fibrogen announces china fda approval of cta to conduct pivotal phase 2/3 clinical trial of roxadustat in anemia associated with lower risk mds

* Fibrogen inc - fibrogen is conducting all clinical trials and regulatory submissions in both u.s. And china

* Fibrogen inc - company expects to initiate this phase 2/3 study in second half of 2017

* In addition, company anticipates initiating a u.s. Phase 3 mds clinical trial in q3 of 2017

* Fibrogen inc - fibrogen will retain all regulatory licenses and manufacturing permits in china for roxadustat in anemia associated with lower risk mds Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below